BOLD

Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026. “We are encouraged by the progress of the KOMODO-1 trial," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “We continue to expand the body of evidence supporting BBI-940’s kinesin degradation mechanism, with our recent AACR poster demonstrating anti-tumor activity and tumor regression across multiple ecDNA+ cancer models. These findings further strengthen our confidence in the therapeutic potential of BBI-940 as we advance the program through a first-in-human clinical trial.” Business Highlights and Upcoming Milestones BBI-940 Novel Kinesin Degrader Clinical Program Enrollment is ongoing in KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology-1), a first-in-human clinical trial of BBI-940 in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer who have progressed following treatment with a cyclin-dependent kinase 4 and/or 6 (CDK4/6) inhibitor plus endocrine therapy, as well as patients with triple-negative breast cancer luminal androgen receptor subtype (TNBC-LAR). Initial safety and efficacy clinical proof-of-concept data are expected within the Company’s existing cash runway timeline. Validating Kinesin Degradation Data Presented at 2026 AACR Annual Meeting In vitro and in vivo study data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, which demonstrated that genetic depletion and pharmacologic degradation of a novel kinesin (Kinesin) cause ecDNA mis-segregation, ecDNA reduction, and reduced viability of ecDNA positive (ecDNA+) cancer cells. Further, selective degradation of Kinesin in a panel of tumor cell lines demonstrated sensitivity across multiple tumor types, including 32% of breast cancer cell lines, including those positive for ecDNA and FGFR1 gain. This molecularly defined sub...

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. "With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options. BBI-940 is designed to disrupt ecDNA segregation and inheritance, a differentiated mechanism for targeting chromosomally unstable cancers. The Boundless team is focused on clinical execution and reaching an initial proof-of-concept readout within our existing cash runway," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. Business Highlights and Upcoming Milestones BBI-940 novel Kinesin degrader program In January 2026, the U.S. Food and Drug Administration accepted the Company’s Investigational New Drug application for BBI-940, a novel, selective, oral Kinesin degrader. KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology-1), a first-in-human clinical trial of BBI-940 in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer who have progressed following treatment with a cyclin-dependent kinase 4 and/or 6 (CDK4/6) inhibitor plus endocrine therapy, as well as patients with triple-negative breast cancer luminal androgen receptor subtype (TNBC-LAR), is open for enrollment. Boundless expects to deliver initial safety and efficacy clinical proof-of-concept data within its existing cash runway timeline. POTENTIATE clinical trial of BBI-355 and BBI-825 In January 2026, Boundless announced its intention to cease enrollment in the Phase 1/2 POTENTIATE trial evaluating the combination of BBI-355 and BBI-825 based on market considerations, available clinical data, and prioritization of its BBI-940 program. Fourth Quarter and Full Year 2025 Financial Results Cash Position: Cash, cash equivalents, a...

Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate in the first half of 2026 $118 million in cash supports operations into first half of 2028, through expected proof-of-concept clinical readouts for both programs SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended September 30, 2025. “We are advancing a pipeline rooted in tumor-enabling ecDNA biology to bring forward innovative therapies for patients with oncogene-amplified cancers,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “Enrollment is underway in the BBI-355/BBI-825 combination arm of the POTENTIATE trial, and we are excited to advance BBI-940, our novel, orally bioavailable Kinesin degrader into the clinic in the first half of 2026, as we work to deliver a meaningful impact for both patients and shareholders.” Research and Development Highlights and Upcoming Milestones POTENTIATE clinical trial of BBI-355 and BBI-825 The combination arm of the Phase 1/2 POTENTIATE trial evaluating BBI-355 and BBI-825 in oncogene-amplified cancers is actively enrolling. The Company expects to deliver initial proof-of-concept clinical data within its existing cash runway timeline. BBI-940 novel Kinesin program targeting ecDNA segregation and inheritance The Company expects to submit an investigational new drug (IND) application for BBI-940 and initiate a first-in-human Phase 1 clinical trial in the first half of 2026. Initial proof-of-concept clinical data are expected within the Company’s existing cash runway timeline. Third Quarter 2025 Financial Results Cash Position: Cash, cash equivalents, and short-term investments totaled $117.6 million as of September 30, 2025. Research and Development (R&D) Expenses: R&D expenses were $10.7 million for the third quarter of 2025, compared to $14.1 million for the same period in 2024. General and Administrative (G&A) Expenses: G&A expenses were $4.5 million for the third quarter of 2025, compared to $4.6 millio...

BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of 2028, through expected proof-of-concept clinical readouts for both programs SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended June 30, 2025. “We are executing with sharpened focus on programs that we believe have the strongest scientific rationale and greatest potential to impact patients with oncogene-amplified cancers,” said Zachary Hornby, President and CEO of Boundless Bio. “We are excited to advance our BBI-355/BBI-825 combination in the clinic and to progress BBI-940, our development candidate in our novel kinesin program, toward IND submission, as we work to make a meaningful impact for both patients and shareholders.” Research and Development Highlights and Upcoming Milestones POTENTIATE clinical trial The Company believes recent preclinical data provide a strong mechanistic rationale to combine BBI-355, its novel, selective, oral CHK1 inhibitor, with BBI-825, its novel, selective, oral RNR inhibitor, for synergistic anti-tumor activity without overlapping toxicity, and with a dosing regimen that does not require continuous administration. The BBI-355/BBI-825 combination arm of the POTENTIATE trial is open for enrollment. The Company expects to deliver initial proof-of-concept clinical data within its existing cash runway timeline. Novel Kinesin program targeting ecDNA segregation and inheritance Boundless selected BBI-940 as its development candidate for its novel program targeting a previously undrugged kinesin. Boundless expects to submit an investigational new drug (IND) application for BBI-940 in the first half of 2026 and to deliver initial proof-of-concept clinical data within its existing cash runway timeline. Second Quarter 2025 Financial Results Cash Position: Cash, cash equivalents, and short-term investments totaled $127.1 million as of June 30, 2025. Research and Development (R&D) Expenses: R...

Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2025. “Boundless remains committed to delivering new therapeutic options to patients with high unmet need oncogene amplified cancers,” said Zachary Hornby, President and CEO of Boundless Bio. “We look forward to providing a clinical data update on our BBI-355 program later this year. Additionally, we expect to nominate a development candidate for our novel Kinesin program by mid-year, with plans to submit an IND in the first half of 2026." Research and Development Highlights and Upcoming Milestones BBI-355, a novel, oral, potent CHK1 inhibitor designed to target replication stress in oncogene-amplified cancers Enrollment is ongoing in the Phase 1/2 POTENTIATE trial. Preliminary clinical proof-of-concept safety and antitumor activity data are expected in the second half of 2025. Novel Kinesin program targeting ecDNA segregation and inheritance Boundless expects to nominate a development candidate for its preclinical program targeting a previously undrugged kinesin by mid-2025, with an investigational new drug (IND) submission planned for the first half of 2026. Recent Data Presentations Preclinical data from studies conducted with Boundless’s ribonucleotide reductase (RNR) inhibitor, BBI-825, were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting. These data suggest that the combination of BBI-825 with mutant-specific, pan, and multi-RAS targeting inhibitors delayed or prevented acquired resistance in colorectal cancer preclinical models. Boundless continues to preclinically evaluate BBI-825 in various treatment settings. First Quarter 2025 Financial Results Cash Position: Cash, cash equivalents, and short-term investm...

BBI-355 Phase 1/2 POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development candidate nomination by mid-2025, with IND submission expected in the first half of 2026 With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027 SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2024. “We made important strides in 2024 as we became a public company and continued to advance BBI-355, our oral, selective CHK1 inhibitor in the Phase 1/2 POTENTIATE trial in patients with oncogene amplified cancers, and we look forward to reporting preliminary proof-of-concept data in the second half of this year,” said Zachary Hornby, President and CEO of Boundless Bio. “Additionally, we have continued to identify new targets and are advancing an oral degrader of a novel kinesin identified by our Spyglass platform. We are on track to nominate a development candidate for our Kinesin program by mid-year, with the intention to submit an IND in the first half of 2026. We look forward to the year ahead as we continue to advance our pipeline to address the significant unmet need in patients with oncogene amplified cancers.” Research and Development Highlights and Upcoming Milestones BBI-355, a novel, oral, potent CHK1 inhibitor designed to target replication stress in oncogene-amplified cancers Enrollment in the Phase 1/2 POTENTIATE clinical trial evaluating BBI-355 as a monotherapy and combination agent in patients with locally advanced or metastatic solid tumors with oncogene amplifications is ongoing. ECHO, a proprietary diagnostic for the detection of ecDNA amplified oncogenes, is in use in the POTENTIATE trial. Boundless expects to report preliminary clinical proof-of-concept safety and antitumor activity data in the second half of 2025. Novel Kinesin program targeting ecDNA segregation and inheritance Boundless is advancing a preclinical program targeting a previously undrugged kinesin tha...